Real-World data reveals immunotherapy Combo's impact on esophageal cancer

NCT ID NCT05142709

Completed Knowledge-focused Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study analyzed medical records from 1197 patients in China with advanced esophageal cancer who received immunotherapy (anti-PD-1) plus chemotherapy as their first treatment. The goal was to see how long patients lived and how long the cancer stayed under control in everyday medical practice, not just in a controlled trial. The results help doctors understand the real-world benefits of this combination therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Anyang cancer hospital

Anyang, Henan, China
Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center

Shenzhen, Guangdong, China
Fudan University Shanghai cancer center

Shanghai, Shanghai Municipality, 200032, China
Fujian Cancer Hospital & Fujian Medical University Cancer Hospital

Fuzhou, Fujian, China
Henan Cancer Hospital

Zhengzhou, Henan, China
Huai'an first hospital

Huai'an, Jiangsu, China
Jiangsu cancer Hosipital

Nanjing, Jiangsu, China
Jiangxi Cancer Hospital

Nanchang, Jiangxi, China
Nantong cancer hospital

Nantong, Jiangsu, China
Sichuan cancer hospital

Chengdu, Sichuan, China
The 1st affiliated hospital of Nanchang University

Nanchang, Jiangxi, China
The 1st affiliated hospital of Xiamen University

Xiamen, Fujian, China
The 2nd affiliated hospital of Bengbu medical University

Bengbu, Anhui, China
The 2nd affiliated hospital of Nanchang University

Nanchang, Jiangxi, China
The 2nd affiliated hospital of Wenzhou medical university

Wenzhou, Zhejiang, China
The 2nd people's hospital of Anhui province

Hefei, Anhui, China
The 4th affiliated hospital of Hebei Medical University

Shijiazhuang, Hebei, China
The First Affiliated Hospital of Air Force Medical University

Xi'an, Shaanxi, China
The Northern Jiangsu People's Hospital

Yangzhou, Jiangsu, China
Wuhan University Zhongnan hospital

Wuhan, Hubei, China
Yancheng the 3rd hospital

Yancheng, Jiangsu, China
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China
Zhongnan University Xiangya Hospital

Changsha, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.